Subcutaneous Administration of Bortezomib: A Pilot Survey of Oncology Nurses

Subcutaneous (SC) administration of the proteasome inhibitor bortezomib was approved in the United States and European Union in 2012. There is limited guidance regarding how to administer SC bortezomib and a general lack of clear direction on optimal techniques for administering SC chemotherapy inje...

Descripción completa

Detalles Bibliográficos
Autores principales: Martin, Jasmine R., Beegle, Nancy L., Zhu, Yanyan, Hanisch, Ellen M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press 2015
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4677804/
https://www.ncbi.nlm.nih.gov/pubmed/26705492

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4677804/
https://www.ncbi.nlm.nih.gov/pubmed/26705492

Ejemplares similares